| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/14/2005 | WO2003083069A3 Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb |
| 04/14/2005 | WO2003063573A3 Method for treating diseases with omega interferon |
| 04/14/2005 | WO2003027228A3 Receptors and membrane-associated proteins |
| 04/14/2005 | WO2003015712A3 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin |
| 04/14/2005 | WO2002079417A3 Methods of delivery of exogenous proteins to the cytosol and uses thereof |
| 04/14/2005 | WO2000051613A3 Upper hitch link |
| 04/14/2005 | US20050080468 Methods and apparatus for treating diseased tissue |
| 04/14/2005 | US20050080257 Benzo'fisoindole derivatives with affinity to the ep4 receptor |
| 04/14/2005 | US20050080144 Oligoamine compounds and derivatives thereof for cancer therapy |
| 04/14/2005 | US20050080117 Substituted benzoxazoles as estrogenic agents |
| 04/14/2005 | US20050080107 Inhibitor of phosphodiesterase enzyme, 2-(4-(3-cyclopentyloxy-4-difluoromethoxyphenyl)-4-cyanopiperidin-1-yl)acetic acid monohydrate; treating inflammatory diseases, diabetics, allergic diseases, autoimmune diseases, ocular diseases, osteoporosis, Parkinson's disease, dementia; chemical intermediates |
| 04/14/2005 | US20050080097 5-[1-(hydroxymethyl)propyl]amino-7-benzylamino-3-isopropyl(methyl, ethyl)pyrazolo[4,3-d]pyrimidine for inhibiting cell proliferation, cancer, or psoriasis, rheumatoid arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, and neurodegerative diseases |
| 04/14/2005 | US20050080096 Condensed heterocyclic compounds |
| 04/14/2005 | US20050080081 Substituted oxazolidinones and their use in the field of blood coagulation |
| 04/14/2005 | US20050080080 Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors |
| 04/14/2005 | US20050080075 Formulations, conjugates, and combinations of drugs for the treatment of neoplasms |
| 04/14/2005 | US20050080069 comprises Potassium tetrachloroplatinate and lignohumic acid ammonium salts; nontoxic |
| 04/14/2005 | US20050080062 preventing or delaying the progression of hormone receptor breast cancer following estrogen antagonist therapy by subsequent therapy with an estrogen depleting agent prior to disease progression |
| 04/14/2005 | US20050080058 New vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments |
| 04/14/2005 | US20050080055 Method of treating breast cancer with androgen receptor antagonists |
| 04/14/2005 | US20050080050 Lipid analogs for treating viral infections |
| 04/14/2005 | US20050080029 Administering to the cell the compound to be delivered, an organic halide, and/or a carrier; ultrasound may also be applied |
| 04/14/2005 | US20050080026 Nucleic acid molecule of MAP kinase interacting kinase gene family or polypeptide encoded thereby or fragment or variant of nucleic acid molecule, polypeptide or antibody, aptamer or receptor recognizing a nucleic acid molecule of gene family or polypeptide encoded thereby; treating metabolic diseases |
| 04/14/2005 | US20050080020 Hydroxylated indirubin derivatives |
| 04/14/2005 | US20050080006 Apo2L/TRAIL formulations including lyophilized and crystal compositions; may be used in inducing apoptosis in mammalian cells including cancer cells by exposing mammalian cells to an effective amount of an Apo-2 ligand formulation described herein |
| 04/14/2005 | US20050079605 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| 04/14/2005 | US20050079575 Human receptor molecules |
| 04/14/2005 | US20050079572 Expression vector comprising nuclelotide sequences coding brain acid soluble protein 1 (BASP1) for use in prevention and treatment of infection, cell proliferative, inflammatory and autoimmune disorders; gene therapy; immunotherapeutics |
| 04/14/2005 | US20050079538 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, agonists, and antagonists; drug screening; anticarcinogenic agents |
| 04/14/2005 | US20050079503 Peptide comprising zinc binding of ubiquination protein for use as tool in identifying modulators for treatment and prevention of inflammation, reproductive and cell proliferation disorders |
| 04/14/2005 | US20050079209 Esters of L-carnitine of alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 04/14/2005 | US20050079173 Antibody that binds said inhibitor protein; interfering diagnostically or therapeutically with a wnt signal path; treatment of eye disorders, bone disorders, or tumors |
| 04/14/2005 | US20050079163 Administering retroviral vector containing nucleic acid encoding a gene; antiproliferative agents; antitumor agents |
| 04/14/2005 | US20050079148 Biocompatible polymer designed to release nitric oxide; extensively cross-linked polyamine-derivatized divinylbenzene; sustained release, potentiation |
| 04/14/2005 | US20050079136 Therapy for pain, appetite inttensifiers, multiple sclerosis and asthma; drug delivery |
| 04/14/2005 | DE10343365A1 Pharmazeutische Formulierungen von Xanthogenaten und Hemmstoffen der viralen Nukleinsäurereplikation Pharmaceutical formulations of xanthates and inhibitors of viral nucleic acid replication |
| 04/14/2005 | DE10342423A1 Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden The use of fumaric acid derivatives for the prophylaxis and treatment of genomic damage |
| 04/14/2005 | CA2582437A1 Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them |
| 04/14/2005 | CA2545639A1 Regulation of matrix metalloproteinases by psp94 family members |
| 04/14/2005 | CA2541823A1 Hypoxia responsive human cngh 0002 genes and polypeptides |
| 04/14/2005 | CA2541018A1 Human prostate cancer cell factor(s) that induce stem cell commitment and osteogenesis |
| 04/14/2005 | CA2540666A1 Glucocerebroside treatment of disease |
| 04/14/2005 | CA2540537A1 New use, pharmaceutical preparations as well as a process for their production |
| 04/14/2005 | CA2540502A1 Use of a compound of formula (i) as an inhibitor of aromatase for therapeutic purposes and compounds of formula (1) thereas |
| 04/14/2005 | CA2540343A1 Indole derivatives |
| 04/14/2005 | CA2540289A1 Substituted indole derivatives |
| 04/14/2005 | CA2539748A1 Substituted benzazoles and use thereof as inhibitors of raf kinase |
| 04/14/2005 | CA2539339A1 Compounds and compositions as protein kinase inhibitors |
| 04/14/2005 | CA2470908A1 Therapy for cancer |
| 04/13/2005 | EP1522583A2 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sina) |
| 04/13/2005 | EP1522543A1 Use Steroid sulphatase inhibitors for the manufacture of a medicament for the treatment of an oestrogen dependent tumour |
| 04/13/2005 | EP1522540A1 Azaarene derivatives |
| 04/13/2005 | EP1522313A1 Combination therapy of radiation and valdecoxib for the treatment of neoplasia |
| 04/13/2005 | EP1522309A1 Lipophilic extracts of hypericum perforatum for the therapy of cancer |
| 04/13/2005 | EP1522308A1 Use of chlorophyll or analogues for the prevention of cytotoxic effects of dietary heme on the intestinal mucosa |
| 04/13/2005 | EP1521845A1 Method for detecting increased susceptibility to tumours |
| 04/13/2005 | EP1521839A1 Methods of making viral particles having a modified cell binding activity and uses thereof |
| 04/13/2005 | EP1521832A2 Genes |
| 04/13/2005 | EP1521828A2 Production of polyketides |
| 04/13/2005 | EP1521824A2 Nucleic acid-associated proteins |
| 04/13/2005 | EP1521822A2 Protein modification and maintenance molecules |
| 04/13/2005 | EP1521779A1 Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same |
| 04/13/2005 | EP1521776A2 Neoplasm specific antibodies and uses thereof |
| 04/13/2005 | EP1521768A2 RNA INTERFERENCE MEDIATED INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 04/13/2005 | EP1521766A2 SPLICEOSOME MEDIATED RNA i TRANS /i -SPLICING AND CORRECTION OF FACTOR VIII GENETIC DEFECTS USING SPLICEOSOME MEDIATED RNA TRANS SPLING |
| 04/13/2005 | EP1521765A1 Bafilomycin-like metabolite from a novel micromonospora species |
| 04/13/2005 | EP1521752A1 Novel macrocycles for the treatment of cancer |
| 04/13/2005 | EP1521750A1 Novel macrocycles for the treatment of cancer diseases |
| 04/13/2005 | EP1521748A1 Novel anthracene derivatives and the use thereof as a medicament |
| 04/13/2005 | EP1521747A2 Receptor-type kinase modulators and methods of use |
| 04/13/2005 | EP1521746A1 Quinazolinone modulators of nuclear receptors |
| 04/13/2005 | EP1521740A2 Probucol derivatives |
| 04/13/2005 | EP1521735A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 04/13/2005 | EP1521733A1 Modulators of the glucocorticoid receptor |
| 04/13/2005 | EP1521594A2 Endogenous retrovirus polypeptides linked to oncogenic transformation |
| 04/13/2005 | EP1521591A1 Use of pthrp antagonists for treating renal cell carcinoma |
| 04/13/2005 | EP1521583A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo (2,1-b)-quinazolinone derivatives |
| 04/13/2005 | EP1521577A1 Methods of using isothiazole derivatives to treat cancer or inflammation |
| 04/13/2005 | EP1521575A1 Aqueous dispersions of nanometric or micrometric particles for encapsulating chemical compounds |
| 04/13/2005 | EP1480736A4 Microcapsules having high carotenoid content |
| 04/13/2005 | EP1465912A4 Novel chimeric tnf ligands |
| 04/13/2005 | EP1458702B1 Luminacin analogs and uses thereof |
| 04/13/2005 | EP1366050B1 Condensed pyrazindione derivatives as pde inhibitors |
| 04/13/2005 | EP1335706B1 Process fo r the production of microspheres of pancreatic enzymes with high stability |
| 04/13/2005 | EP1289955B1 Piperidines for use as orexin receptor antagonists |
| 04/13/2005 | EP1274399B1 Liposomes containing an entrapped compound in supersaturated solution |
| 04/13/2005 | EP1257270B1 A method for synthesizing leflunomide |
| 04/13/2005 | EP1214101A4 Method for detecting and killing epithelial cancer cells |
| 04/13/2005 | EP1212052B1 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 04/13/2005 | EP1183353B1 Modified chimeric polypeptides with improved pharmacokinetic properties |
| 04/13/2005 | EP1077709B1 Arsenic sulfide compounds free of arsenic oxide for the treatment of hematological cancers |
| 04/13/2005 | EP1015469B1 Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| 04/13/2005 | EP0880507B1 Quinazoline derivatives as antitumor agents |
| 04/13/2005 | EP0728210B1 Thrombin mutants |
| 04/13/2005 | CN1606623A Production of stilbenes in transgenic plants and the method of producing thereof |
| 04/13/2005 | CN1606569A Human antibodies that have mn binding and cell adhesion-neutralizing activity |
| 04/13/2005 | CN1606568A Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor |
| 04/13/2005 | CN1606566A Integrin targeting compounds |
| 04/13/2005 | CN1606563A Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents |
| 04/13/2005 | CN1606556A Triazolo-quinolin derivatives useful as adenosine receptor ligands |